Aspiriant LLC’s Cencora COR Stock Holding History

Aspiriant LLC’s Portfolio COR Stock Details COR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-603	Closed	-$204K	–	341
2025 Q4	$204K	Buy	+603	New	+$206K	0.01%	315
2024 Q2	–	Sell	-1,088	Closed	-$264K	–	294
2024 Q1	$264K	Hold	1,088	–	–	0.01%	272
2023 Q4	$223K	Buy	+1,088	New	+$212K	0.01%	278

Other funds holding COR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aspiriant LLC's COR Position: Q1 2026 in Review

Aspiriant LLC sold out of Cencora (COR) in Q1 2026, closing a stake of 603 shares — an estimated $204K sold.

Aspiriant LLC first reported a position in COR in Q4 2023 and held it in 3 quarters. The position peaked at $264K in Q1 2024. 1,426 funds tracked by Wall St. Rank hold COR as of Q1 2026.

Aspiriant LLC reported no remaining Cencora position as of Q1 2026 after selling out during the quarter.
Aspiriant LLC sold 603 Cencora shares in Q1 2026, an estimated $204K.
Aspiriant LLC first reported a position in Cencora in Q4 2023 and held it in 3 quarters.
Aspiriant LLC's Cencora position peaked at $264K in Q1 2024.
1,426 funds tracked by Wall St. Rank held Cencora as of Q1 2026.

Based on Aspiriant LLC's 13F filing for Q1 2026, filed 12 May 2026.